17005-Urothelial Cancer-NA-517

Urothelial Cancer

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Address

3700 W State Route 89A
Sedona, AZ 86336
P: (928) 204-4163

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.